Median overall survival in patients who received cetuximab was 25.0 months ( 95 % CI 20.2-30 .5 ) compared with 24.0 months ( 19.8-28 .6 ) in those who did not ( HR 1.07 , 95 % CI 0.84-1 .35 ; p = 0.29 ) .